Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Succinate-cytochrome c reductase (SCR) is an integrated multienzyme system located in the mitochondrial inner membrane, representing the coupled activities of Complex II (succinate:ubiquinone oxidoreductase) and Complex III (ubiquinol:cytochrome c oxidoreductase). [5, 8, 14] Its primary biological function is to catalyze the transfer of electrons from succinate to cytochrome c via the ubiquinone pool, a vital segment of the respiratory chain that supports the generation of a proton gradient for ATP synthesis. [12, 16] Genetic defects in the subunits composing this system are linked to mitochondrial encephalomyopathies, Leigh syndrome, and various cancers where the accumulation of succinate functions as a tumorigenic oncometabolite. [1, 11, 12] SCR is a significant target in toxicology for predicting drug-induced mitochondrial dysfunction, as many pharmaceutical agents and environmental toxins can inhibit its activity, leading to energy depletion and oxidative stress. [3, 8] Furthermore, it is targeted by experimental anticancer compounds known as mitocans, such as MKT-077, which aim to induce apoptosis in malignant cells by disrupting mitochondrial electron flux and increasing superoxide production. [4, 10, 15]
Inhibition of the integrated electron transfer from succinate to cytochrome c, disrupting the mitochondrial respiratory chain, reducing ATP production, and increasing the leakage of electrons to form reactive oxygen species.
6 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Succinate-cytochrome c reductase (SCR) (SCR).